INmune Bio (NASDAQ:INMB) Releases Quarterly Earnings Results, Beats Expectations By $0.14 EPS

INmune Bio (NASDAQ:INMB - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.14, Zacks reports.

INmune Bio Stock Performance

NASDAQ:INMB traded down $0.06 during mid-day trading on Tuesday, hitting $7.75. The stock had a trading volume of 128,525 shares, compared to its average volume of 244,086. The company's 50 day simple moving average is $8.43 and its 200 day simple moving average is $6.39. The stock has a market cap of $206.08 million, a price-to-earnings ratio of -3.55 and a beta of 1.93. INmune Bio has a twelve month low of $4.32 and a twelve month high of $12.72.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the company. RODMAN&RENSHAW raised INmune Bio to a "strong-buy" rating in a research report on Tuesday, January 28th. Rodman & Renshaw began coverage on shares of INmune Bio in a research report on Tuesday, January 28th. They issued a "buy" rating and a $23.00 price objective on the stock. Scotiabank raised their target price on shares of INmune Bio from $22.00 to $23.00 and gave the company a "sector outperform" rating in a research report on Tuesday, February 11th. Finally, Maxim Group increased their price objective on shares of INmune Bio from $22.00 to $30.00 and gave the stock a "buy" rating in a research note on Thursday, February 13th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $22.80.

Remove Ads

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.